Generalized Anxiety Disorder Market size is estimated to reach $8.1 billion by 2027, growing at a CAGR of 2.6% during the forecast period 2022-2027. Generalized Anxiety Disorder (GAD) is a condition with excessive tension, worrying and agitation regarding every day events. The defining characteristic of GAD is exorbitant, generalized worry that the individual finds difficult to curb and is backed by a series of somatic symptoms. This constitutes a universal introduction to the psychopathology of GAD. While panic disorder and generalized anxiety disorder (GAD) share certain typical symptoms, like inordinate worrying, they are two independent and different mental health conditions. Acquiring knowledge regarding these two typical mental health conditions may be the earliest step to assisting oneself or a loved one. Symptoms of agoraphobia are frequently comparable to certain symptoms of generalized anxiety disorder. These symptoms involve acute fear and anxiety connected to public places, crowds, enclosed spaces, wide-open spaces and public transportation.
Cognitive behavioral therapy (CBT) basically aspires to relieve generalized anxiety disorder (GAD) symptoms, which arise from habitual, inflexible and spiraling systems of interaction between somatic, cognitive and emotional responses to conscious threats. Benzodiazepines decrease the magnitude of physiological symptoms of GAD, like muscle tension, headaches, panic attacks, sweating, insomnia and restlessness. Clinical investigations have clearly displayed the efficiency of buspirone in the treatment of generalized anxiety disorder without the ancillary pharmacology of former anxiolytics. The enhanced diagnostic criteria pertaining to generalized anxiety disorder is set to drive the Generalized Anxiety Disorder Market. The increasing predominance of generalized anxiety disorder owing to greater stress in daily life and requiring the application of benzodiazepines is set to propel the growth of the Generalized Anxiety Disorder Industry during the forecast period 2022-2027. This represents the Generalized Anxiety Disorder Industry Outlook.
Download Sample Report : https://www.industryarc.com/pdfdownload.php?id=15869
Generalized Anxiety Disorder Market Report Coverage
The “Generalized Anxiety Disorder Market Report - Forecast (2022-2027)” by Industry ARC, covers an in-depth analysis of the following segments in the Generalized Anxiety Disorder Market.
Key Takeaways
- Geographically, North America (Generalized Anxiety Disorder market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the increasing predominance of anxiety disorders including generalized anxiety disorder which may require the application of benzodiazepines, in the North American region.
- Generalized Anxiety Disorder Market growth is being driven by the greater pervasiveness of anxiety ailments in women when compared to men and the surging awareness regarding generalized anxiety disorder which may require application of cognitive behavioral therapy across the world. However, the enormous count of failed clinical trials and declining R&D are some of the major factors hampering the growth of Generalized Anxiety Disorder Market.
- Generalized Anxiety Disorder Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Generalized Anxiety Disorder Market report.
Generalized Anxiety Disorder Market Segment Analysis - by Therapeutics
The Generalized Anxiety Disorder Market based on therapeutics can be further segmented into Antidepressant, Buspirone, Benzodiazepines, Others. The Antidepressant Segment held the largest Generalized Anxiety Disorder market share in 2021. This growth is owing to the heightening application of antidepressants for treatment of generalized anxiety disorder attributed to antidepressants being the first line of treatment for patients enduring generalized anxiety disorder. Benzodiazepines may be habit-forming and are therefore utilized on a short-term basis generally being the last choice of treatment for generalized anxiety disorder. The beneficial application of antidepressants for treatment of generalized anxiety disorder (GAD) owing to GAD presenting a high co-morbidity ratio with major depressive disorder and dysthymia is further propelling the growth of the Antidepressant segment.
Furthermore, the Buspirone segment is estimated to grow with the fastest CAGR of 3.1% during the forecast period 2022-2027 owing to Buspirone being better than placebo in enhancing anxiety and depressive symptoms in generalized anxiety disorder (GAD) patients who have coexisting depressive symptoms.
Generalized Anxiety Disorder Market Segment Analysis - by Therapies
The Generalized Anxiety Disorder Market based on therapies can be further segmented into Interpersonal Therapy, Behavior Therapy, Cognitive Behavioral Therapy, Mindfulness Based Cognitive Therapy. The Cognitive Behavioral Therapy Segment held the largest Generalized Anxiety Disorder market share in 2021. This growth is owing to the surging application of cognitive behavioral therapy for the treatment of generalized anxiety disorder. Cognitive behavioral therapy (CBT) is the most extensively utilized therapy for anxiety disorders. Research has demonstrated it to be efficient in the treatment of panic disorder, phobias, social anxiety disorder and generalized anxiety disorder, amidst numerous additional conditions. Agoraphobia Therapy can be performed by utilizing cognitive behavioral therapy. The consideration of cognitive behavioral therapy as the “gold standard” psychotherapy for generalized anxiety disorder is further propelling the growth of this segment.
Furthermore, the Mindfulness Based Cognitive Therapy segment is estimated to grow with the fastest CAGR of 3.3% during the forecast period 2022-2027 owing to the decrease in anxiety symptoms in generalized anxiety disorder through the application of mindfulness based cognitive therapy that integrates elements of cognitive-behavioral therapy (CBT) and mindful practices.
Generalized Anxiety Disorder Market Segment Analysis - by Geography
The Generalized Anxiety Disorder Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and Rest of the World. North America (Generalized Anxiety Disorder Market) held the largest Generalized Anxiety Disorder market share with 36% of the overall market in 2021. The growth of this region is owing to the rising pervasiveness of generalized anxiety disorder and the increasing awareness regarding anxiety amidst people in the North American region. Cases of panic disorder and Agoraphobia are also noted in the North American region. The existence of key players like Abbott Laboratories in U.S. and the surging count of novel product launches are further propelling the growth of the Generalized Anxiety Disorder Industry in the North American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the increasing stress and the busy lifestyles of people in the Asia-Pacific region. The burgeoning facilities to detect anxiety ailments like generalized anxiety disorder, agoraphobia and panic disorder are further fueling the progress of the Generalized Anxiety Disorder Market in the Asia-Pacific region.
Inquiry Before Buying : https://www.industryarc.com/reports/request-quote?id=15869
Generalized Anxiety Disorder Market Drivers
Increasing Predominance of Generalized Anxiety Disorder is Projected to Drive the Growth of Generalized Anxiety Disorder Market:
Benzodiazepines, at times indicated as benzos, are a category of medications typically utilized for their tranquilizing and anti-anxiety impacts. They can be efficient in the treatment of anxiety. Typical applications for benzodiazepines involve the treatment of anxiety, panic attacks and insomnia. Examples of benzodiazepines utilized for the treatment of anxiety-connected to panic disorder or additional anxiety ailments involve Xanax (alprazolam): which is prescribed for short-term alleviation of anxiety symptoms and Klonopin (clonazepam): which is prescribed to treat panic disorder and panic attacks. Generalized Anxiety Disorder is a condition characterized by excessive tension, worrying and nervousness regarding every day events, As per the Anxiety & Depression Association of America (ADAA), Generalized Anxiety Disorder (GAD) influences 6.8 million mature grown-ups or 3.1% of the U.S. population, yet only 43.2% are accepting treatment. Further updates by ADAA indicate that women are twice as likely to be influenced as men and generalized anxiety disorder frequently happens with considerable depression. The increasing predominance of generalized anxiety disorder is therefore fueling the growth of the Generalized Anxiety Disorder Market during the forecast period 2022-2027.
Soaring Applications of Cognitive Behavioral Therapy for Generalized Anxiety Disorder are Expected to Boost the Growth of the Generalized Anxiety Disorder Industry:
People with generalized anxiety disorder worry regarding issues that may not occur and are always on great alert. Therefore, they have greater anxiety, find it hard to curb their emotions and always wish to curb their thoughts. Cognitive-behavioral therapy (CBT) essentially aspires to alleviate generalized anxiety disorder (GAD) symptoms, which arise from habitual, inflexible, and spiraling systems of interaction between somatic, cognitive and emotional responses to conscious threats. Cognitive-behavioral therapy for generalized anxiety disorder is typically offered in 10- to 15-hour-long sessions however can involve added sessions relying on the severity of symptoms, the existence of comorbidity, patient resistance to the treatment approach, therapist competence and the number of constituents included into CBT. Cognitive behavioral therapy (CBT) integrates Beck’s therapy and relaxation methods. Clinical research confirms that CBT and relaxation methods assist in treating generalized anxiety disorder. Context Cognitive behavior therapy (CBT) is efficient for late-life generalized anxiety disorder (GAD). However, only pilot investigations have been organized in primary care, where older mature grown-ups most frequently look for treatment. These kinds of soaring applications of cognitive behavioral therapy for generalized anxiety disorder are therefore driving the growth of the Generalized Anxiety Disorder Industry, thereby contributing to the Generalized Anxiety Disorder Industry Outlook, during the forecast period 2022-2027.
Generalized Anxiety Disorder Market Challenges
Limitations Pertaining to Generalized Anxiety Disorder (GAD) are Hampering the Growth of the Generalized Anxiety Disorder Market:
As per Anxiety Statistics on disturbmenot.co, more than 90% of people with generalized anxiety disorder have another psychiatric diagnosis. The poor diagnosis rate of generalized anxiety disorder owing to the lack of a suitable diagnosis test is one principal issue. The application of psychotherapy for anxiety disorders comes with its limitations, Psychodynamic therapy typically takes longer than cognitive behavioral therapy (CBT), at times lasting for numerous years. Therapy sessions are unstructured. Certain patients are uncomfortable speaking about their history or past issues, which can defer any progress. The side-effects of medicines include habit forming nature, dry mouth and nausea. These issues are thus hampering the growth of the Generalized Anxiety Disorder Market.
Buy Now : https://www.industryarc.com/purchasereport.php?id=15869
Generalized Anxiety Disorder Industry Outlook
Development of generalized anxiety disorder pipeline drugs, technological advancement in the pharmaceutical industry, surging public and private partnerships in the healthcare sector for R&D of generalized anxiety disorder drugs and acquisitions are key strategies adopted by players in the Generalized Anxiety Disorder Market. The top 10 companies in the Generalized Anxiety Disorder market are:
- Eli Lilly and Company
- GlaxoSmithKline Pharmaceuticals Limited
- Pfizer, Inc.
- Abbott Laboratories
- Bristol-Myers Squibb
- Actavis Pharmaceutical Company
- F. Hoffmann-La Roche
- Sumitomo Dainippon Pharma
- MindMed
- VistaGen Therapeutics, Inc
Recent Developments
- In October 2021, VistaGen Therapeutics extended clinical development of PH94B with initiation of Phase 2A trial in adjustment disorder. Investigation introduced Phase 2A clinical program planned to analyze PH94B’s potential in numerous added anxiety disorders. Phase 2A investigation in adjustment disorder is to run in parallel with continuing Phase 3 investigations in acute treatment of social anxiety disorder.
- In December 2020, Eli Lilly and Company and Prevail Therapeutics Inc. declared a definitive agreement for Lilly to gain Prevail for $22.50 per share in cash (or an aggregate of nearly $880 million) payable at closing plus one non-tradable contingent value right ("CVR") worth up to $4.00 per share in cash (or an aggregate of nearly $160 million), for a total consideration of up to $26.50 per share in cash (or an aggregate of nearly $1.040 billion).
- In April 2020, VistaGen Therapeutics declared plans to extend clinical development of PH94B, its first-in-class rapid-onset neuroactive nasal spray, to involve treatment of adjustment disorder owing to stressors connected to the COVID-19 pandemic. Adjustment disorder is an emotional or behavioral reaction thought-out as inordinate or out of proportion to a stressful event or principal life alteration, happening within three months of the stressor, and/or considerably harming a person's social, occupational and/or other vital areas of functioning.
For more Lifesciences and Healthcare Market reports, please click here
